Tricuspid Valve

This channel is dedicated to news and trends in tricuspid valve interventions, surgical and transcatheter, to manage regurgitation and valve stenosis. The tricuspid valve is a rapidly growing area in structural heart interventions. Minimally invasive transcatheter tricuspid valve replacement (TTVR) and repair using transcatheter edge to edge repair (TEER) clips are expected to become a new standard of care in the next couple years, partly because open heart tricuspid surgery has historically has poor outcomes.

Abbott TriClip device for TEER

TriClip triumphs: Tricuspid edge-to-edge repair linked to strong 30-day outcomes in real-world setting

The new study, published in the Journal of the American College of Cardiology, focused on more than 500 patients treated with Abbott’s TriClip device in Europe.

July 18, 2023
TricValve Transcatheter Bicaval Valves System and HeartMate II LVAD. A team of interventional cardiologists has made a bit of history, using a new transcatheter device to treat tricuspid regurgitation (TR) in a high-risk heart failure patient who with a previously implanted left ventricular assist device (LVAD). It represents the first time this particular device, the TricValve Transcatheter Bicaval Valves System from P+F Products, has been implanted in a patient with this particular LVAD, the HeartMate II.

Cardiologists shed new light on treating severe tricuspid regurgitation in high-risk heart failure patients

The 80-year-old patient was experiencing severe TR and already had a HeartMate II LVAD. 

June 15, 2023
The LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) device

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

The new valve was placed inside the damaged valve via a catheter that is inserted through a small incision in the patient's neck. 

April 13, 2023
Paul Sorajja, MD, director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital, was the principal investigator for the late-breaking TRILUMINATE pivotal trial at the American College of Cardiology (ACC) 2023 meeting and explains details of this landmark trial. #ACC #ACC23 #triluminate

TRILUMINATE trial may pave the way for FDA clearance for tricuspid valve clip device

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

March 13, 2023
ACC.23 Together with the World Congress of Cardiology

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

March 4, 2023
Edwards Lifesciences Corporation has shared new one-year data on the safety and effectiveness of its Evoque transcatheter tricuspid valve replacement (TTVR) system among patients with tricuspid regurgitation (TR)

Edwards shares new one-year data on transcatheter tricuspid valve replacement

The new findings, presented at the PCR London Valves 2022 conference, focused on mortality and heart failure hospitalization rates. 

November 28, 2022
The tricuspid valve anatomy is ofrten complicated for transcatheter structural heart interventions (TTVR) by the placement of pacemaker or ICD leads.

VIDEO: Addressing tricuspid valve regurgitation with new transcatheter interventions 

Joao Cavalcante, MD, of the Minneapolis Heart Institute, discusses new structural heart interventions to treat tricuspid valve regurgitation.

September 21, 2022
Three transcatheter tricuspid valve repair and replacement (TTVR) technologies that will likely see FDA clearance in. the next couple years include the Edwards Evoque transcatheter tricuspid valve (top left), Abbott TriClip (below) and the Edwards Lifesciences Pascal clip device (right).

Tricuspid valve therapies moving ahead of mitral therapies seeking market approval

The complexity of the mitral valve has slowed development of new transcatheter technologies, and it now seems much more likely that transcatheter devices for tricuspid valve will push ahead to gain FDA clearances.

September 12, 2022

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup